Ignite Creation Date:
2024-05-05 @ 11:42 PM
Last Modification Date:
2024-10-26 @ 10:38 AM
Study NCT ID:
NCT01399593
Status:
TERMINATED
Last Update Posted:
2017-10-03
First Post:
2011-07-19
Brief Title:
Safety Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
Sponsor:
Alexion Pharmaceuticals Inc
Organization:
Alexion Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Open-label Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization Therapy
Status:
TERMINATED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Did not achieve statistical significance for primary endpoint
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection AMR in sensitized recipients of a living donor kidney transplant requiring desensitization therapy
Detailed Description:
The main objective of this study was to evaluate the safety and efficacy of eculizumab to prevent AMR in sensitized recipients of living donor kidney transplants requiring desensitization therapy prior to transplantation The primary endpoint focused on acute AMR during the first 9 weeks post-transplantation
Patients were to be vaccinated against N meningitidis at least 14 days prior to study drug initiation and revaccinated 30 days later If not vaccinated 14 days prior prophylactic antibiotics were to be administered Pre-transplant infectious disease assessment was to be performed as part of the screening assessment
Patients were to undergo desensitization therapy according to the practice of the local transplant center prior to transplantation and this desensitization practice was to be uniformly applied for all patients at that center throughout the study The actual length of desensitization for an individual patient was based on the clinical judgment of the Transplant Center team Rituximab was prohibited in all patients as part of the pre-transplantation desensitization therapy due to potential pharmacodynamic interactions
The control group was designed to test eculizumab against the best available care referred to as standard of care or SOC consisting of plasmapheresis PP andor intravenous immunoglobulin IVIg The best available care consisting of PP and IVIg was chosen because these modalities combined represented the most prevalent therapy reported in the literature and were the best available therapies at the time of this protocols inception as per the transplant community
Patients were to be vaccinated against N meningitidis at least 14 days prior to study drug initiation and revaccinated 30 days later If not vaccinated 14 days prior prophylactic antibiotics were to be administered Pre-transplant infectious disease assessment was to be performed as part of the screening assessment
Patients were to undergo desensitization therapy according to the practice of the local transplant center prior to transplantation and this desensitization practice was to be uniformly applied for all patients at that center throughout the study The actual length of desensitization for an individual patient was based on the clinical judgment of the Transplant Center team Rituximab was prohibited in all patients as part of the pre-transplantation desensitization therapy due to potential pharmacodynamic interactions
The control group was designed to test eculizumab against the best available care referred to as standard of care or SOC consisting of plasmapheresis PP andor intravenous immunoglobulin IVIg The best available care consisting of PP and IVIg was chosen because these modalities combined represented the most prevalent therapy reported in the literature and were the best available therapies at the time of this protocols inception as per the transplant community
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BB-IND 100003 | OTHER | FDA IND 100003 | None |
| 2010-019630-28 | EUDRACT_NUMBER | None | None |